- Home
- CXAI vs TPST Comparison
CXAI vs TPST Comparison
Compare CXAI & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CXAI
- TPST
- Stock Information
- Founded
- CXAI N/A
- TPST 2011
- Country
- CXAI United States
- TPST United States
- Employees
- CXAI N/A
- TPST N/A
- Industry
- CXAI EDP Services
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- CXAI Technology
- TPST Health Care
- Exchange
- CXAI Nasdaq
- TPST Nasdaq
- Market Cap
- CXAI 22.4M
- TPST 24.5M
- IPO Year
- CXAI N/A
- TPST N/A
- Fundamental
- Price
- CXAI $1.01
- TPST $7.94
- Analyst Decision
- CXAI
- TPST Hold
- Analyst Count
- CXAI 0
- TPST 3
- Target Price
- CXAI N/A
- TPST $30.00
- AVG Volume (30 Days)
- CXAI 713.7K
- TPST 51.4K
- Earning Date
- CXAI 05-20-2025
- TPST 05-13-2025
- Dividend Yield
- CXAI N/A
- TPST N/A
- EPS Growth
- CXAI N/A
- TPST N/A
- EPS
- CXAI N/A
- TPST N/A
- Revenue
- CXAI $6,548,000.00
- TPST N/A
- Revenue This Year
- CXAI N/A
- TPST N/A
- Revenue Next Year
- CXAI $60.00
- TPST N/A
- P/E Ratio
- CXAI N/A
- TPST N/A
- Revenue Growth
- CXAI N/A
- TPST N/A
- 52 Week Low
- CXAI $0.76
- TPST $5.35
- 52 Week High
- CXAI $3.76
- TPST $44.59
- Technical
- Relative Strength Index (RSI)
- CXAI 44.84
- TPST 63.92
- Support Level
- CXAI $0.94
- TPST $5.92
- Resistance Level
- CXAI $1.08
- TPST $7.06
- Average True Range (ATR)
- CXAI 0.10
- TPST 0.46
- MACD
- CXAI -0.01
- TPST 0.20
- Stochastic Oscillator
- CXAI 14.23
- TPST 68.10
About CXAI CXApp Inc.
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.